Idorsia presents Phase 2 pediatric insomnia trial data for daridorexant at Sleep Europe 2026

• Idorsia flagged new daridorexant clinical and real-world findings slated for presentation at Sleep Europe 2026 in Maastricht on Oct. 20-23.
• A placebo-controlled Phase 2 pediatric insomnia study tested multiple doses in ages 10-17, marking the first investigational DORA dataset in children.
• Two real-world studies will report routine-use outcomes, focusing on sleep improvement, daytime functioning, quality of life, depressive symptoms, work productivity.
• An adult Phase 3 analysis will assess daridorexant in insomnia patients with objectively measured short sleep duration, covering efficacy and safety.
• A six-country review will examine how DORAs have shifted insomnia prescribing away from traditional sedative-hypnotics, shaped by reimbursement policies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610081145OMX_____CNEWS_EN_GNW1001277001_en) on October 08, 2026, and is solely responsible for the information contained therein.